Detection of a Novel Serotonin Receptor Subtype (5‐HT<sub>1E</sub>) in Human Brain: Interaction with a GTP‐Binding Protein

Sigrun Leonhardt, Katharine Herrick‐Davis, Milt Titeler

Journal of Neurochemistry · 1989 · 177 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

Abstract: [ 3 H]Serotonin (5‐hydroxytryptamine, [ 3 H]5‐HT) was used as a radioligand probe of brain 5‐HT receptors in homogenates of human cortical tissue. Two binding sites were detected in the presence of 1 μ M pindolol (to block 5‐HT 1A and 5‐HT 1B receptors), and 100 n M mesulergine (to block 5‐HT 1c and 5‐HT 2 receptors). One of these sites demonstrated high affinity for 5‐carboxyamidotryptamine (5‐CT) and er‐gotamine, consistent with the known pharmacology of the 5‐HT 1D receptor; the second site demonstrated low affinity for 5‐CT and ergotamine. Computer‐assisted analyses indicated that both drugs displayed high affinities ( K i values of 1.1 n M and 0.3 n M for 5‐CT and ergotamine, respectively) for 55% of the sites and low affinities ( K i values of 910 n M and 155 n M for 5‐CT and ergotamine, respectively) for 45% of the sites. To investigate the non‐5‐HT 1D component of the binding, 100 n M 5‐CT (to block 5‐HT 1A , 5TTT 1B , and 5‐HT 1D receptors) was coincubated with [ 3 H]5‐HT, membranes, and mesulergine. The remaining [ 3 H]5‐HT binding (hereafter referred to as “5‐HT 1E ”) displayed high affinity and saturability ( K D , 5.3 n M ; B max , 83 fmol/mg) in human cortical tissue. Competition studies with nonradioactive drugs indicated that, of the drugs tested, 5‐CT and ergotamine displayed the highest selectivity for the 5‐HT 1D site versus the 5‐HT 1E site. The interaction of the 5‐HT 1E site with a GTP‐binding protein was demonstrated; the nonhydrolyzable derivatives of GTP, guanosine 5′‐ 0 ‐(3‐thiotriphosphate) (GTPγS) and 5′‐guanylylimidodiphosphate [Gpp(NH)p], potently inhibited binding of [ 3 H]5‐HT to the 5‐HT 1E site (IC 50 values of 16 and 172 n M , respectively) while adenosine 5′‐ 0 ‐(3‐thiotriphosphate) (ATPγS) and 5′‐adenylylimidodi‐phosphate [App(NH)p] were without effect. The high affinity of 5‐HT for the site, the unique pharmacological profile of the site, and the interaction of the site with a GTP‐binding protein indicate that this site represents a unique 5‐HT receptor subtype heretofore undescribed, and which we propose to call 5‐HT 1E in keeping with the current system of nomenclature in the 5‐HT receptor field.

References

32